Guillain –Barré syndrome in patients treated with immune checkpoint inhibitors

ConclusionAs complements to the safety data from RCTs, the current pharmacovigilance research helps establish a more detailed overview of ICI-related GBS, which facilitates the understanding of this rare adverse drug effect.

http://link.springer.com/10.1007/s00415-021-10404-0

Source: Journal of Neurology - January 21, 2021 Category: Neurology Source Type: research